citalopram has been researched along with Lethargy in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Lethargy: A general state of sluggishness, listless, or uninterested, with being tired, and having difficulty concentrating and doing simple tasks. It may be related to DEPRESSION or DRUG ADDICTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Uher, R | 1 |
| Frey, BN | 1 |
| Quilty, LC | 1 |
| Rotzinger, S | 1 |
| Blier, P | 1 |
| Foster, JA | 1 |
| Müller, DJ | 1 |
| Ravindran, AV | 1 |
| Soares, CN | 1 |
| Turecki, G | 1 |
| Parikh, SV | 1 |
| Milev, R | 1 |
| MacQueen, G | 1 |
| Lam, RW | 1 |
| Kennedy, SH | 1 |
| Nil, R | 1 |
| Lütolf, S | 1 |
| Seifritz, E | 1 |
| Rizo, C | 1 |
| Deshpande, A | 1 |
| Ing, A | 1 |
| Seeman, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Integrated Biological Markers for the Prediction of Treatment Response in Depression[NCT01655706] | Phase 3 | 211 participants (Actual) | Interventional | 2012-04-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citalopram and Lethargy
| Article | Year |
|---|---|
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Di | 2020 |
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Di | 2020 |
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Di | 2020 |
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Aripiprazole; Citalopram; Depressive Di | 2020 |
2 other studies available for citalopram and Lethargy
| Article | Year |
|---|---|
Residual symptoms and functionality in depressed outpatients: A one-year observational study in Switzerland with escitalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder, Major; | 2016 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Col | 2011 |